Anavex's CEO discussed plans to focus on EMA submission, address concerns about patient data variations, clarify stock offering intentions, explain dose dependency in Alzheimer's data, and mentioned compiling open-label 96-week data for potential FDA engagement. For more details, refer to the full earnings call transcript.